These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30143452)

  • 1. CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis.
    Zhou Y; Wang XB; Qiu XP; Shuai Zhang ; Wang C; Zheng F
    Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):529-541. PubMed ID: 30143452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of APC, GSTP1 and SOCS1 promoter methylation with the risk of hepatocellular carcinoma: a meta-analysis.
    Liu M; Cui LH; Li CC; Zhang L
    Eur J Cancer Prev; 2015 Nov; 24(6):470-83. PubMed ID: 25853848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of RASSF1A hypermethylation with risk of HBV/HCV-induced hepatocellular carcinoma: A meta-analysis.
    Peng JL; Wu JZ; Li GJ; Wu JL; Xi YM; Li XQ; Wang L
    Pathol Res Pract; 2020 Oct; 216(10):153099. PubMed ID: 32853942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p16 Methylation was associated with the development, age, hepatic viruses infection of hepatocellular carcinoma, and p16 expression had a poor survival: A systematic meta-analysis (PRISMA).
    Lv X; Ye G; Zhang X; Huang T
    Medicine (Baltimore); 2017 Sep; 96(38):e8106. PubMed ID: 28930859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma.
    Csepregi A; Ebert MP; Röcken C; Schneider-Stock R; Hoffmann J; Schulz HU; Roessner A; Malfertheiner P
    BMC Cancer; 2010 Jun; 10():317. PubMed ID: 20569442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of P14 and MGMT gene methylation in hepatocellular carcinomas: a meta-analysis.
    Li CC; Yu Z; Cui LH; Piao JM; Liu M
    Asian Pac J Cancer Prev; 2014; 15(16):6591-6. PubMed ID: 25169493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of low p16INK4a and p15INK4b mRNAs expression with their CpG islands methylation with human hepatocellular carcinogenesis.
    Qin Y; Liu JY; Li B; Sun ZL; Sun ZF
    World J Gastroenterol; 2004 May; 10(9):1276-80. PubMed ID: 15112341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
    Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
    Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population.
    Wu HC; Yang HI; Wang Q; Chen CJ; Santella RM
    Carcinogenesis; 2017 Oct; 38(10):1021-1028. PubMed ID: 28981677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between promoter methylation in the GSTP1 gene and hepatocellular carcinoma development: a meta-analysis.
    Li QF; Li QY; Gao AR; Shi QF
    Genet Mol Res; 2015 Jun; 14(2):6762-72. PubMed ID: 26125884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of GSTP1 and P16 promoter methylation with the risk of HBV-related hepatocellular carcinoma: a meta-analysis.
    Li Q; Deng C; Zhang T; Li X
    Onco Targets Ther; 2018; 11():5789-5796. PubMed ID: 30254471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma.
    Roncalli M; Bianchi P; Bruni B; Laghi L; Destro A; Di Gioia S; Gennari L; Tommasini M; Malesci A; Coggi G
    Hepatology; 2002 Aug; 36(2):427-32. PubMed ID: 12143052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).
    Cao Z; Wei L; Zhu W; Yao X
    Medicine (Baltimore); 2018 Mar; 97(12):e0182. PubMed ID: 29561434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and prognostic effects of
    Xia L; Zhang W; Gao L
    Biomarkers; 2019 Nov; 24(7):700-711. PubMed ID: 31382782
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer.
    Tang B; Li Y; Qi G; Yuan S; Wang Z; Yu S; Li B; He S
    Sci Rep; 2015 Sep; 5():13563. PubMed ID: 26338139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan.
    Lin YW; Chen CH; Huang GT; Lee PH; Wang JT; Chen DS; Lu FJ; Sheu JC
    Eur J Cancer; 1998 Oct; 34(11):1789-95. PubMed ID: 9893670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant promoter methylation of SOCS-1 gene may contribute to the pathogenesis of hepatocellular carcinoma: a meta-analysis.
    Zhao RC; Zhou J; He JY; Wei YG; Qin Y; Li B
    J BUON; 2016; 21(1):142-51. PubMed ID: 27061542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKN2A methylation in esophageal cancer: a meta-analysis.
    Zhou C; Li J; Li Q
    Oncotarget; 2017 Jul; 8(30):50071-50083. PubMed ID: 28637022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between p16 gene promoter methylation and clinicopathologic features of colorectal cancer: a meta-analysis of 27 cohort studies.
    Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
    DNA Cell Biol; 2014 Oct; 33(10):729-38. PubMed ID: 24979649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-γ +874A/T polymorphism and hepatocellular carcinoma risk: a meta-analysis.
    Zhou H; Wang L; Li X; Song J; Jiang T; Wu X; Zhou S
    Med Sci Monit; 2015 Mar; 21():689-93. PubMed ID: 25739411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.